Reading the Wegovy pill prescribing information starts with a surprise: the tablet has no separate booklet. Novo Nordisk combines the weekly shot and daily pill in one DailyMed label marked "Revised: 6/2026".
The header prints "Initial U.S. Approval: 2017" for the semaglutide molecule, not the pill. The FDA record for NDA 218316 lists original tablet approval on "12/22/2025" as a "Type 3 - New Dosage Form". DailyMed shows a June 18, 2026 update date and published Version 19 on June 30, 2026.
Our Wegovy injection prescribing information guide covers the weekly pens. Here is what the June 2026 label says about the daily tablet, section by section.
What the Wegovy pill prescribing information says in Section 1
Section 1 pairs Wegovy tablets with "a reduced calorie diet and increased physical activity" for two adult uses. First, the pill is indicated "to reduce the risk of major adverse CV events" in adults with cardiovascular disease and obesity or overweight. Those events are cardiovascular death, non-fatal heart attack, or non-fatal stroke.
Second, it is indicated "to reduce excess body weight and maintain weight reduction long term" in adults with obesity. That use also covers overweight with "at least one weight-related comorbid condition" (another health issue tied to weight).
Section 1 prints no BMI cutoff. It omits the shot's indication for adolescents aged 12 and older and its indication for MASH, a liver disease involving inflammation and scarring. Combining Wegovy with other semaglutide products or any GLP-1 agonist is "not recommended".
Boxed warning and contraindications (Section 4)
A boxed warning notes that semaglutide caused thyroid C-cell tumors in rodents. It states: "It is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans". MTC is a rare thyroid cancer.
Routine calcitonin blood tests or thyroid ultrasounds have uncertain value for early detection. Section 4 contraindicates Wegovy in patients with a personal or family history of MTC. It also contraindicates Wegovy in patients who have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), a rare genetic tumor disorder.
Those bans apply only to MTC and MEN 2, not every thyroid diagnosis. The only other contraindication is "a prior serious hypersensitivity reaction to semaglutide or to any of the excipients" (inactive ingredients) in Wegovy.
Wegovy pill instructions, escalation, and missed doses (Section 2)
Section 2 records the branded pill's dosing rules, while a licensed prescriber sets each patient's actual plan. Section 2.1 specifies taking one pill "orally once daily on an empty stomach in the morning with water (up to 4 ounces)" and no other liquid.
The label states to "Swallow tablets whole" and never "split, crush, chew or dissolve" them. Patients should not take more than one tablet per day. Afterward, it specifies waiting "at least 30 minutes before eating food, drinking beverages or taking other oral medications".
Sections 11 and 12.3 note each pill pairs semaglutide with magnesium stearate and salcaprozate sodium (SNAC) to aid stomach absorption. The label estimates absolute bioavailability, the share reaching the bloodstream, at approximately 1% to 2% after oral tablet administration; see oral semaglutide. Section 11 lists no SNAC milligram amount.
Table 2 in Section 2.3 sets a four-step schedule that rises every 30 days:
| Label stage | Days | Once-daily tablet dosage |
|---|---|---|
| Starting dosage | 1 through 30 | 1.5 mg |
| Dosage escalation | 31 through 60 | 4 mg |
| Dosage escalation | 61 through 90 | 9 mg |
| Maintenance dosage | 91 and onward | 25 mg |
Section 2.3 states: "If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation". For 25 mg intolerance, a prescriber may consider the 1.7 mg weekly Wegovy shot.
Section 2.4 states: "If a dose of WEGOVY tablets is missed, skip the missed dose and take the next dose the following day". That differs from the weekly shot's two-day rule. Section 2.5 covers switching between the 2.4 mg shot and 25 mg pill.
As of October 17, 2026, the day this article was written, Novo Nordisk reported observational OCTANE data on September 30, 2026. In "194 patients" switching from shots who stayed on the pill three months, self-reported weight fell "4.1% or 8.8 lbs". The study lacked a continuing-shot group and noted "Real-world studies evaluate associations and cannot determine causality"; see switching to the Wegovy pill.
Warnings, Wegovy 25 mg tablet side effects, and trial data (Sections 5, 6, and 14)
Sections 5.1 through 5.10 cover ten safety warnings. Section 5.2 warns of acute pancreatitis, including "fatal and non-fatal hemorrhagic or necrotizing pancreatitis" (severe pancreas inflammation).
The label identifies persistent or severe abdominal pain, sometimes radiating to the back, as a possible symptom. If pancreatitis is suspected, it directs discontinuation of Wegovy and appropriate medical management.
For gallstones (cholelithiasis), Section 5.3 says "gallbladder studies and appropriate clinical follow-up are indicated". Section 5.4 warns that patients with diabetes using Wegovy with insulin or a sulfonylurea have an increased risk of low blood sugar. That hypoglycemia warning covers any insulin secretagogue (insulin-releasing pill) and includes severe episodes.
Section 5.5 covers kidney injury from dehydration after vomiting or diarrhea, which sometimes required hemodialysis (machine blood filtering). Section 5.6 states "WEGOVY is not recommended in patients with severe gastroparesis" (delayed stomach emptying).
Sections 5.7 to 5.9 cover serious allergic reactions, diabetic retinopathy (diabetes eye disease) monitoring, and sustained resting heart-rate increases. Section 5.10 warns of pulmonary aspiration (stomach contents entering the lungs) during general anesthesia or deep sedation. Patients should tell providers before planned procedures, as evidence cannot set one stopping window for everyone.
In Section 6.1, the Wegovy tablets label prints no standalone table of common side-effect rates. Instead, it summarizes Study 7 (204 tablet-treated adults without diabetes) and points to Table 3 for the 2.4 mg shot. It states: "In the clinical trial with WEGOVY 25 mg tablets, the types and frequency of common adverse reactions were similar to those listed in Table 3".
Those Table 3 reaction types include nausea, diarrhea, vomiting, constipation, abdominal pain, and dysesthesia (altered skin sensation). The 2025 OASIS 4 trial in the New England Journal of Medicine assigned 205 adults without diabetes to the 25 mg pill and 102 to placebo. Week-64 weight change was −13.6% versus −2.2% in the paper's abstract, or −13.6% versus −2.4% in Label Table 11; see OASIS 4 results.
Section 6.2 also notes postmarketing reports like ileus (intestinal blockage) and fecal impaction, which cannot establish frequency rates. Verified tablet trial safety figures include:
| Measure and source | Wegovy 25 mg tablets | Placebo |
|---|---|---|
| Gastrointestinal adverse events (OASIS 4 abstract) | 74.0% | 42.2% |
| Discontinuation for adverse reactions (Label §6.1) | 6.9% | 5.9% |
| Discontinuation for GI reactions (Label §6.1) | 3.4% | 2% |
| Severe GI reactions (Label §5.6) | 2% | 0% |
| Cholelithiasis / gallstones (Label §5.3, §6.1) | 2.5% | 1% |
Wegovy pill drug interactions, breastfeeding, and storage (Sections 7, 8, and 16)
Section 7 notes that slowed stomach emptying can affect how the body absorbs other oral drugs. It advises considering extra monitoring for medicines that require tight blood-level control. It states: "In a drug interaction study with the semaglutide tablet, levothyroxine exposure was increased 33% (90% CI: 1.25-1.42)".
Exposure means total drug in the blood over time—about one-third higher here—not the peak level. The 2021 crossover study in 45 healthy adults tested single-dose 600 mcg levothyroxine with 14 mg oral semaglutide, not the 25 mg pill. Peak thyroxine stayed unchanged, and the authors noted "Monitoring of thyroid parameters should be considered" rather than automatic dose cuts.
Sections 8.1 and 8.3 direct stopping Wegovy when pregnancy is recognized and "at least 2 months before they plan to become pregnant". Section 8.2 states "breastfeeding is not recommended during treatment with WEGOVY tablets". SNAC and its breakdown products pass into breast milk and could build up in infants.
The weekly shot contains no SNAC, so its label weighs breastfeeding benefits against clinical need and infant risks. Section 8.4 states that tablet safety and effectiveness have not been established in pediatric patients. In Section 8.5, only 16 tablet-trial patients (8%, or under 1 in 10) were aged 65 to 74, and 5 (2%) were 75 or older.
Section 8.6 notes weight reduction in type 2 diabetes was unstudied with the pill, where lower blood levels may cause an inadequate response. Sections 3 and 16 describe 30-count bottles of white-to-light-yellow "novo" tablets (round at 1.5, 4, and 9 mg; oval at 25 mg).
Section 16 directs storing tablets at "20°C to 25°C (68°F to 77°F)" in "the original bottle until use to protect tablets from moisture". For injectable options, a November 2023 FDA announcement cleared branded Zepbound (tirzepatide) injection, a different molecule targeting GLP-1 and GIP receptors.
What the Wegovy pill package insert means for compounded medications
The June 2026 Wegovy pill package insert covers only Novo Nordisk's branded products. A shared ingredient name does not transfer the pill's SNAC absorption, dose ladder, storage rules, or trial results.
Semaglutide and tirzepatide prescribed through Promise are dispensed by a licensed U.S. compounding pharmacy. Each is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulations offered here are not FDA-approved.
An October 1, 2026 FDA statement on unapproved GLP-1 drugs notes that "compounded drugs are not FDA approved". It adds that "the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed". Even though compounded formulations are not FDA-approved, a licensed provider may still prescribe — that decision is between you and your doctor.
Provider directions and the pharmacy label govern any compounded preparation. At Promise, a licensed provider reviews every request and not everyone qualifies.
